Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
CAR-T cell therapy: current limitations and potential strategies1213
Acute myeloid leukemia: current progress and future directions391
CAR T-cell therapy in multiple myeloma: more room for improvement112
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies106
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies106
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment101
Acute promyelocytic leukemia current treatment algorithms98
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia96
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm95
Extramedullary disease in multiple myeloma: a systematic literature review93
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report93
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage87
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia85
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm83
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma81
Chromosome 1q21 abnormalities in multiple myeloma78
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study70
Global burden of hematologic malignancies and evolution patterns over the past 30 years65
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia62
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)62
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up 62
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life61
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis61
Core binding factor acute myelogenous leukemia-2021 treatment algorithm61
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis58
Genetic and epigenetic determinants of diffuse large B-cell lymphoma58
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma54
Management of chronic myeloid leukemia in 2023 – common ground and common sense54
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab53
Extramedullary disease in multiple myeloma53
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy52
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis50
Diffuse large B-cell lymphoma: new targets and novel therapies50
Comprehensive Review of AL amyloidosis: some practical recommendations47
A simple additive staging system for newly diagnosed multiple myeloma47
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel46
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia45
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)45
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results45
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantati43
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera42
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden41
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study41
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment41
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis41
0.065325021743774